159 results on '"Anaclerico, Barbara"'
Search Results
2. Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian 'Back to Life' project
3. P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.
4. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
5. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients
6. Symptomatic Mucocutaneous Toxicity of Hydroxyurea in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: The Mister Hyde Face of a Safe Drug
7. Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the “Ph1‐negative Myeloproliferative Neoplasms Latium Group”
8. Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization
9. Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up
10. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey
11. Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome
12. Treatment of Philadelphia‐negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors
13. High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia
14. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
15. Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia
16. Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN
17. Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome
18. Latium (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN
19. Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis
20. Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis
21. Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis
22. EBMT 2015 The Impact of HLA Matching on the Clinical Outcome of Hematopoietic Stem Cell Transplantation from Volunteer Unrelated Donors According to the Uniform, Prospective Transplant Program of the Rome Transplant Network 22 - 25 March 2015 • Istanbul, Turkey
23. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
24. Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms
25. The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients
26. Evolving Criteria of Donor Selection for Allogeneic Transplant in Acute Myeloid Leukemia
27. Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?
28. Survival of Patients with High Risk Hematological Malignancy after Allogeneic Transplant from HLA Identical Siblings Is Comparable to That of Patients Transplanted from Haploidentical, Unmanipulated Bone Marrow Donor: Results of a Matched-Pair Analysis from the Rome Transplant Network
29. Prognostic Factors for Thrombosis-Free Survival and Overall Survival in Polycytemia Vera: A Retrospective Analysis of 623 Patients Series with Long Follow-up
30. Autopsy Analysis On Epidemiology and Site of Involvement Of Invasive Fungal Infections (IFI) In Hematological Malignancies : A Retrospective Study at Hematologic Tertiary Care Department
31. Prospective Phase II Single-Center Study of the Safety of a Single Very High Dose of Liposomal Amphotericin B for Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia
32. The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?
33. Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment
34. Risk Factors for Thrombosis Vary According to Age in Patients with Essential Thrombocythemia: a Retrospective Analysis of 1090 Patients from the “Gruppo Laziale SMPC Ph Negative “,
35. Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea
36. A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloprolypherative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results
37. Skin Toxicity of Hydroxyurea In Ph- Myeloproliferative Neoplasms: Incidence and Clinical Features
38. Post Tandem Autologous Stem Cell Transplant Maintenance Therapy with Bortezomib Improves Remission Duration and Quality of Response in Multiple Myeloma Patients.
39. Standard Versus High Dose Lenograstim in Adults with Hematological Malignancies for Peripheral Blood Progenitor Cell Mobilization: Results of a Retrospective Study on Behalf of Rome Transplant Network.
40. Rituximab + IEV/MINE Second Line Approach in Relapsed/Refractory Non Hodgkin Lymphoma (NHL): Efficacy and Safety
41. Treatment with Sequential Valproic Acid (VPA) +/− Low Doses All Trans Retinoic Acid (LoATRA) and Low Doses Ara-C (LoDAC) for “De Novo” or Relapsed Acute Myeloid Leukaemia (AML).
42. Safety and Tolerability of Intrathecal Liposomal Cytarabine during CNS Prophylaxis in Patients with Non Hodgkin Lymphoma and Acute Lymphoblastic Leukemia.
43. Darbepoietin in Autologous Peripheral Blood Stem Cell Transplantation (ASCT): A Pilot Study.
44. Liposomal Cytarabine in the Central Nervous System (CNS) Prophylaxis of Elderly Patients with Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) and Undifferentiated Acute Leukemia (UAL): Preliminary Results of a Single-Center Experience.
45. Diagnostic Approach to CD5+/CD23+ Leukemic Non-Hodgkin Lymphomas Lacking Lymphnode Histopathology.
46. Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4and of the BCR/ABLfusion genes correlates with a significantly better clinical outcome
47. Incidence of Early Adverse Events in Primary Myelofibrosis (PMI). a Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN
48. Possible Role Of Treatment On Secondary Malignancies In Patients Affected By Essential Thrombocytemia
49. Azacitidine In The Treatment Of Ph- Myeloproliferative Neoplasms In Blastic Phase: The Experience Of Gruppo Laziale For The Study Of Ph- SMPC
50. Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.